Every one of those 1 sits in a single category, funding. Apyx Medical Corporation is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Nantahala Capital Management LLC appears in 1 tracked Biotech story from August 13, 2026.
Recent coverage · Nantahala Capital Management LLC
1story
avg impact
0%positive
0%negative
100% neutral
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Nantahala Capital Management LLC
Every one of those 1 sits in a single category, funding. Apyx Medical Corporation is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Nantahala Capital Management LLC appears in 1 tracked Biotech story from August 13, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Nantahala Capital Management LLC. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Nantahala Capital Management LLC is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
